Knights Of Columbus Asset Advisors LLC Affimed N.V. Transaction History

Knights Of Columbus Asset Advisors LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Jan 31, 2023	BUY	$1.1 - $2.45 $98,767 - $219,983	89,789 Added 60.3%	238,699 $295,000
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $291,863 - $494,381	148,910 New	148,910 $307,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.